Director's Dealing

RNS Number : 1878N

Avacta Group PLC

21 October 2016

 

21 October 2016

Avacta Group plc

("Avacta", "the Group" or "the Company")

Director's Dealing

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics, research and diagnostic reagents, announces that Dr. Mike Owen, a Non-Executive Director of the Group, has purchased today 7,763 Ordinary Shares of 10p each in the Group at a price of 90.0 pence per share.

Following this transaction, Dr Owen's total interest in the Group is 7,763 Ordinary Shares of 10p each, representing less than 0.1% of Avacta's issued share capital.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking WG Partners David Wilson Nigel Barnes Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins	Tel: [phone] [e-mail]

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Mike Owen
2.	Reason for the Notification
a)	Position/status	Non - Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Avacta Group Plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 10p
	Identification code	GB00BYYW9G87
b)	Nature of the transaction	Purchase of 10p Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 90.0 pence 7,763
d)	Aggregated information: ·      Aggregated volume ·      Price	See above
e)	Date of the transaction	21 October 2016
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHLLFVIIELLFIR